PL3612519T3 - Związki fenylo-2-hydroksy-acetyloamino-2-metylo-fenylowe - Google Patents

Związki fenylo-2-hydroksy-acetyloamino-2-metylo-fenylowe

Info

Publication number
PL3612519T3
PL3612519T3 PL18718570T PL18718570T PL3612519T3 PL 3612519 T3 PL3612519 T3 PL 3612519T3 PL 18718570 T PL18718570 T PL 18718570T PL 18718570 T PL18718570 T PL 18718570T PL 3612519 T3 PL3612519 T3 PL 3612519T3
Authority
PL
Poland
Prior art keywords
phenyl
acetylamino
hydroxy
methyl
compounds
Prior art date
Application number
PL18718570T
Other languages
English (en)
Inventor
Marta Maria CIFUENTES-GARCIA
Maria Cristina GARCIA-PAREDES
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3612519T3 publication Critical patent/PL3612519T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
PL18718570T 2017-04-18 2018-04-11 Związki fenylo-2-hydroksy-acetyloamino-2-metylo-fenylowe PL3612519T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382207 2017-04-18
EP18718570.7A EP3612519B1 (en) 2017-04-18 2018-04-11 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
PCT/US2018/027005 WO2018194885A1 (en) 2017-04-18 2018-04-11 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Publications (1)

Publication Number Publication Date
PL3612519T3 true PL3612519T3 (pl) 2022-05-02

Family

ID=58606227

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21211015.9T PL4039675T3 (pl) 2017-04-18 2018-04-11 Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe
PL18718570T PL3612519T3 (pl) 2017-04-18 2018-04-11 Związki fenylo-2-hydroksy-acetyloamino-2-metylo-fenylowe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL21211015.9T PL4039675T3 (pl) 2017-04-18 2018-04-11 Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe

Country Status (30)

Country Link
US (2) US11655214B2 (pl)
EP (2) EP4039675B1 (pl)
JP (2) JP7110232B2 (pl)
KR (2) KR102575246B1 (pl)
CN (2) CN110831927B (pl)
AU (2) AU2018255191B2 (pl)
BR (1) BR112019021867A2 (pl)
CO (1) CO2019012767A2 (pl)
CR (1) CR20190519A (pl)
CY (1) CY1125150T1 (pl)
DK (2) DK4039675T3 (pl)
ES (2) ES2906847T3 (pl)
FI (1) FI4039675T3 (pl)
HR (2) HRP20241188T1 (pl)
HU (2) HUE057745T2 (pl)
IL (2) IL270005B (pl)
LT (2) LT3612519T (pl)
MX (2) MX389724B (pl)
MY (1) MY199442A (pl)
NZ (1) NZ758291A (pl)
PH (1) PH12019502363B1 (pl)
PL (2) PL4039675T3 (pl)
PT (2) PT4039675T (pl)
RS (2) RS65914B1 (pl)
SA (1) SA519410320B1 (pl)
SG (1) SG11201909680UA (pl)
SI (2) SI4039675T1 (pl)
SM (2) SMT202200100T1 (pl)
WO (1) WO2018194885A1 (pl)
ZA (1) ZA201906811B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65914B1 (sr) * 2017-04-18 2024-10-31 Lilly Co Eli Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja
CA3095156A1 (en) * 2018-03-26 2019-10-03 Icahn School Of Medicine At Mount Sinai Methods of treating minimal residual cancer
US12331054B2 (en) 2019-08-29 2025-06-17 Hibercell, Inc. Perk inhibiting imidazolopyrazine compounds
WO2021041976A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting indolinyl compounds
CN114585606A (zh) * 2019-08-29 2022-06-03 希伯塞尔股份有限公司 抑制perk的化合物
CA3152508A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds
EP4055008A1 (en) 2019-11-06 2022-09-14 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
WO2021231782A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibitors for treating viral infections
WO2021231788A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds to treat viral infections
CN113234029B (zh) * 2021-05-25 2022-03-22 白银康寓信生物科技有限公司 一种2-氨基-3,5-二卤代吡嗪的合成方法
CN121399099A (zh) * 2023-03-30 2026-01-23 希伯塞尔股份有限公司 (r)-2-氨基-5-(4-(2-(3,5-二氟苯基)-2-羟基乙酰胺基)-2-甲基苯基)-n-异丙基烟酰胺的晶形及其使用方法
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
TR199902301T2 (xx) 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2005030933A2 (en) 2003-09-24 2005-04-07 Genera Doo Bone morphogenetic protein (bmp)-7 based diagnosis and treatment of cancer
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
US8211919B2 (en) * 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
AU2009219437B2 (en) 2008-02-25 2014-10-16 Nestec S.A. Drug selection for breast cancer therapy using antibody-based arrays
WO2010080992A1 (en) 2009-01-09 2010-07-15 The Trustees Of The University Of Pennsylvania Regulators of the interferon-alpha receptor 1 (ifnar1) chain of the interferon receptor
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
EP2986286A1 (en) 2013-04-15 2016-02-24 Universita' Degli Studi di Bari Galloyl benzamide-based compounds as jnk modulators
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
JP6493218B2 (ja) 2013-11-08 2019-04-03 小野薬品工業株式会社 ピロロピリミジン誘導体
WO2015136463A1 (en) 2014-03-11 2015-09-17 Glaxosmithkline Intellectual Property (No.2) Limited Chemical compounds acting as perk inhibitors
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
KR102562866B1 (ko) 2014-11-14 2023-08-04 네르비아노 메디칼 사이언시스 에스.알.엘. 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
CN108026102A (zh) * 2015-07-24 2018-05-11 蓝印药品公司 可用于治疗与kit和pdgfr相关的病症的化合物
ES2965081T3 (es) 2016-07-07 2024-04-11 Daewoong Pharmaceutical Co Ltd Derivados 4-aminopirazolo[3,4-d]pirimidinil-azabiciclo y composición farmacéutica que comprende dichos derivados
US20190241573A1 (en) 2016-07-20 2019-08-08 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
CN106748989B (zh) 2016-11-14 2020-03-17 西安交通大学 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用
EP3656382A1 (en) 2017-01-30 2020-05-27 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
RS65914B1 (sr) 2017-04-18 2024-10-31 Lilly Co Eli Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja
KR102740831B1 (ko) 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
EP3492454A1 (en) 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
CA3095156A1 (en) 2018-03-26 2019-10-03 Icahn School Of Medicine At Mount Sinai Methods of treating minimal residual cancer
US11186579B2 (en) 2018-07-06 2021-11-30 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
EP3860578A1 (en) 2018-10-01 2021-08-11 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of inhibitors of stress granule formation for targeting the regulation of immune responses

Also Published As

Publication number Publication date
US11655214B2 (en) 2023-05-23
KR20190140966A (ko) 2019-12-20
US20230373922A1 (en) 2023-11-23
LT3612519T (lt) 2022-03-25
SMT202200100T1 (it) 2022-03-21
LT4039675T (lt) 2024-10-10
JP7110232B2 (ja) 2022-08-01
SA519410320B1 (ar) 2022-05-08
RS65914B1 (sr) 2024-10-31
US12590064B2 (en) 2026-03-31
ES2988739T3 (es) 2024-11-21
RS62933B1 (sr) 2022-03-31
EP4039675B1 (en) 2024-06-12
MX2019012428A (es) 2022-01-28
JP7331212B2 (ja) 2023-08-22
PH12019502363B1 (en) 2023-11-15
AU2018255191A1 (en) 2019-11-07
CN110831927B (zh) 2023-07-14
RU2019136694A (ru) 2021-05-18
HUE057745T2 (hu) 2022-06-28
EP3612519B1 (en) 2021-12-01
DK4039675T3 (da) 2024-09-02
EP4039675A1 (en) 2022-08-10
MX389724B (es) 2025-03-20
AU2022206702B2 (en) 2024-04-11
ES2906847T3 (es) 2022-04-20
AU2022206702A1 (en) 2022-08-11
ZA201906811B (en) 2021-01-27
CO2019012767A2 (es) 2020-04-01
JP2021517555A (ja) 2021-07-26
MY199442A (en) 2023-10-28
SMT202400357T1 (it) 2024-11-15
NZ758291A (en) 2025-11-28
KR20230129627A (ko) 2023-09-08
MX2022001310A (es) 2022-03-02
PH12019502363A1 (en) 2020-12-07
CA3060564A1 (en) 2018-10-25
SG11201909680UA (en) 2019-11-28
KR102575246B1 (ko) 2023-09-06
JP2022141835A (ja) 2022-09-29
BR112019021867A2 (pt) 2020-05-26
WO2018194885A1 (en) 2018-10-25
FI4039675T3 (fi) 2024-09-10
AU2018255191B2 (en) 2022-04-21
HRP20220263T1 (hr) 2022-04-29
RU2019136694A3 (pl) 2021-05-19
CY1125150T1 (el) 2023-06-09
IL288822A (en) 2022-02-01
PT4039675T (pt) 2024-09-16
CN117510405A (zh) 2024-02-06
EP3612519A1 (en) 2020-02-26
SI3612519T1 (sl) 2022-04-29
IL288822B2 (en) 2023-06-01
HUE068023T2 (hu) 2024-12-28
US20210114985A1 (en) 2021-04-22
SI4039675T1 (sl) 2024-10-30
PT3612519T (pt) 2022-02-22
IL270005B (en) 2022-01-01
HRP20241188T1 (hr) 2024-12-06
PL4039675T3 (pl) 2025-01-07
CR20190519A (es) 2020-03-06
DK3612519T3 (da) 2022-03-07
CN110831927A (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
DK3731771T3 (da) V462033dk00
EP3578560A4 (en) QUINAZOLINE COMPOUND
CL2018000524S1 (es) Golilla
EP3609871A4 (en) ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS
EP3589248A4 (en) CRYOTHERAPIES
DE202018003363U8 (de) Handgelenkssphygmomanometer
EP3634404C0 (en) PYRAZOLE-BASED MAGL INHIBITORS
EP3588580A4 (en) SCHOTTKY MOS TRENCH DIODE
DK4039675T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
DK3351526T3 (da) Diisopentylterephthalat
EP3654852A4 (en) TOURNIQUET
EP3634397A4 (en) HETEROCYCLYL POLYMETHINE-BASED IR CHROMOPHORES
DK3568655T3 (da) Rekuperator
DK3571580T3 (da) Load-logical-and-shift-guarded-instruktion
SMT202200173T1 (it) Composti
DK3612237T3 (da) Genterapi
EP3611402A4 (en) SERVO CYLINDER
EP3615471A4 (en) PLASMA PHOTOELECTRONIC IMMUNE SENSOR
DK3576686T3 (da) Brokbind
DK3568506T3 (da) Offeranode
DK3672941T3 (da) Pyridylpyridonforbindelser
LT3668879T (lt) Nauji junginiai
DK3672962T3 (da) Morpholinylpyridonforbindelser
DK3510051T3 (da) Carboxylalkylchitosan
DK3676276T3 (da) Spirothietannukleosider